GT Biopharma, Inc. (GTBP)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
GTBP Insider Trading Activity
GTBP Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Insider Activity of GT Biopharma, Inc.
Over the last 12 months, insiders at GT Biopharma, Inc. have bought $0 and sold $0 worth of GT Biopharma, Inc. stock.
On average, over the past 5 years, insiders at GT Biopharma, Inc. have bought $38,149 and sold $243,268 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $25,000 was made by Breen Michael Martin (Executive Chairman/Interim CEO) on 2023‑04‑11.
List of Insider Buy and Sell Transactions, GT Biopharma, Inc.
| 2023-04-11 | Breen Michael Martin | Executive Chairman/Interim CEO | 50,000 0.123% | $0.50 | $25,000 | -51.54% | ||
| 2023-04-06 | Ohri Manu | CFO & Secretary | 50,000 0.139% | $0.50 | $25,000 | -44.78% | ||
| 2020-12-22 | Sale | Weldon Steven W | 47,978 0.0139% | $0.40 | $19,191 | -7.75% | ||
| 2020-12-22 | Wendel Bruce | 1,815 0.0116% | $8.84 | $16,037 | -7.75% | |||
| 2020-12-21 | Sale | Weldon Steven W | 135,722 0.0465% | $0.32 | $43,645 | +36.27% | ||
| 2020-12-18 | Sale | Weldon Steven W | 50,000 0.018% | $0.30 | $15,000 | +53.68% | ||
| 2020-12-17 | Sale | Weldon Steven W | 100,000 0.0357% | $0.30 | $30,500 | +49.56% | ||
| 2020-12-16 | Sale | Weldon Steven W | 50,000 0.0184% | $0.30 | $15,000 | +57.16% | ||
| 2020-12-15 | Sale | Weldon Steven W | 150,000 0.0538% | $0.31 | $46,000 | +49.46% | ||
| 2020-12-14 | Sale | Weldon Steven W | 146,300 0.0524% | $0.29 | $41,927 | +59.77% | ||
| 2020-12-11 | Sale | Weldon Steven W | 100,000 0.0342% | $0.26 | $25,500 | +71.90% | ||
| 2020-11-16 | Wendel Bruce | 3,268 0.0201% | $3.14 | $10,262 | +150.45% | |||
| 2020-06-02 | Sale | Cataldo Tony | CEO | 4.23M 0.0294% | $0.00 | $4,234 | +15.02% | |
| 2020-05-13 | Sale | Weldon Steven W | CFO | 2.27M 0.0175% | $0.00 | $2,270 | +17.36% | |
| 2019-02-06 | Sale | Cataldo Tony | director | 800,000 0.0025% | $0.00 | $800 | -68.50% | |
| 2019-02-01 | Sale | Urbanski Raymond W. | CEO | 176,980 0.0005% | $0.00 | $177 | -69.87% | |
| 2010-12-27 | Sale | Theorem Group, LLC | 10 percent owner | 360,100 0.0475% | $0.13 | $47,209 | ||
| 2010-12-27 | Sale | DUBE ANSHUMAN | 360,100 0.0475% | $0.13 | $47,209 | |||
| 2010-12-23 | Sale | Theorem Group, LLC | 10 percent owner | 339,900 0.0445% | $0.13 | $44,187 | ||
| 2010-12-23 | Sale | DUBE ANSHUMAN | 339,900 0.0445% | $0.13 | $44,187 |
Insider Historical Profitability
| Cataldo Tony | CEO | 6500000 256.2687% | $15.34M | 0 | 2 | |
| Weldon Steven W | 3720000 146.6646% | $8.78M | 0 | 9 | ||
| Urbanski Raymond W. | CEO | 1351918 53.3007% | $3.19M | 0 | 1 | |
| Post Gary M | 900000 35.4834% | $2.12M | 0 | 5 | ||
| Breen Michael Martin | Executive Chairman/Interim CEO | 656218 25.872% | $1.55M | 1 | 0 | <0.0001% |
| Ohri Manu | CFO & Secretary | 50000 1.9713% | $118,000.00 | 1 | 0 | <0.0001% |
| Wendel Bruce | 5083 0.2004% | $11,995.88 | 2 | 0 | +71.35% | |
| DUBE ANSHUMAN | 0 0% | $0 | 0 | 2 | ||
| Theorem Group, LLC | 10 percent owner | 0 0% | $0 | 0 | 2 |
Historical Insider Profitability vs. Competitors
$18,881,323 | 88 | -48.96% | $6.66M | |
$523,320 | 24 | 94.37% | $7.39M | |
$31,129 | 22 | -11.96% | $6.01M | |
$51,865 | 17 | -38.70% | $6.23M | |
$960,082 | 17 | -6.29% | $5.41M | |
$1,080,165 | 17 | -6.62% | $7.46M | |
$1,558,469 | 16 | -26.98% | $4.67M | |
$139,855 | 11 | -32.84% | $6.48M | |
$309,830 | 10 | -55.78% | $4.17M | |
$8,971,546 | 8 | 6.18% | $7.37M | |
$713,979 | 6 | -14.06% | $4.83M | |
$726,438 | 4 | -72.85% | $4.92M | |
GT Biopharma, Inc. (GTBP) | $76,299 | 4 | 11.60% | $5.99M |
$105,480 | 3 | -97.42% | $4.99M | |
$14,530 | 3 | 62.23% | $5.95M | |
$1,057,000 | 3 | 5.27% | $3.91M | |
$4,423 | 2 | 3.27% | $5.58M | |
$45,452 | 2 | -43.10% | $6.37M | |
$1,049,630 | 1 | -74.91% | $7.33M |
GTBP Institutional Investors: Active Positions
| Increased Positions | 8 | +44.44% | 7,909 | +0.63% |
| Decreased Positions | 4 | -22.22% | 11,173 | -0.9% |
| New Positions | 5 | New | 2,275 | New |
| Sold Out Positions | 2 | Sold Out | 10,110 | Sold Out |
| Total Postitions | 22 | +22.22% | 1M | -0.26% |
GTBP Ownership Change vs Market
Institutional Investor Ownership
| Dekabank Deutsche Girozentrale | $2,887.00 | 38.5% | 1.15M | 0 | 0% | 2024-12-31 |
| Bank Of Montreal /Can/ | $72.00 | 0.97% | 28,951 | -921 | -3.08% | 2024-12-31 |
| Geode Capital Management, Llc | $37.00 | 0.5% | 14,899 | -142 | -0.94% | 2024-12-31 |
| Vanguard Group Inc | $26.00 | 0.35% | 10,504 | 0 | 0% | 2024-12-31 |
| Wells Fargo & Company/Mn | $25.00 | 0.33% | 10,013 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $24.00 | 0.33% | 9,737 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $12.00 | 0.17% | 4,996 | +1,093 | +28% | 2024-12-31 |
| Morgan Stanley | $9.00 | 0.12% | 3,533 | +3,267 | +1,228.19% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $7.00 | 0.1% | 2,917 | +1,274 | +77.54% | 2024-12-31 |
| Newbridge Financial Services Group, Inc. | $4.00 | 0.06% | 1,750 | +1,750 | New | 2024-12-31 |